Immunomodulation and infection: identification of small molecule TLR3 blockers to combat deleterious inflammation in pneumonia
| Autor: | B Pouzet, L Goullieux, C Ravinet-Trillou, J-M Bras, L Leotard, F Pecceu, P-E Rouby, B Martin, C Serradeil-Le Gal, F Sônego |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Lung
business.industry viruses medicine.medical_treatment chemical and pharmacologic phenomena 030208 emergency & critical care medicine Inflammation Critical Care and Intensive Care Medicine medicine.disease 3. Good health Sepsis 03 medical and health sciences Pneumonia 0302 clinical medicine Immune system medicine.anatomical_structure Cytokine 030228 respiratory system Poster Presentation Immunology TLR3 medicine medicine.symptom Receptor business |
| Zdroj: | Critical Care |
| ISSN: | 1364-8535 |
| DOI: | 10.1186/cc14058 |
| Popis: | Pneumonia is a common cause of death worldwide and the leading cause of sepsis and shock in the ICU. Controlling excessive immune stimulation with deleterious consequences for the host organs is a major strategy in severe infections. In addition to viral dsRNA, the immune Toll-like receptor 3 (TLR3) senses RNA released from injured tissues and necrotic cells promoting excessive inflammatory cytokine release in pulmonary epithelial, endothelial and immune cells. Thus, as a potent regulator of the lung immune response, TLR3 represents a specific target to control damaging inflammation in severe lung infections in combination with antimicrobials. Here, we aimed to characterize potent small molecules displaying in vitro and in vivo TLR3 blocker activities and develop several preclinical models to investigate the role of TLR3 in pneumonia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink